title: HER-2/neu is an independent prognostic factor in type I endometrial adenocarcinoma.
abstract: OBJECTIVE
  To define the prognostic significance of HER-2/neu and PTEN expression in patients with endometrioid (type I) endometrial cancer.
  
  
  METHODS
  Seventy-seven patients with endometrioid endometrial carcinoma were included in the study, in a period between 1996 and 2009. Patients with coexisting malignancy and those having incomplete immunohistochemical data or clinical follow-up were excluded. Histological staging was defined according to the revised FIGO staging (2009). Clinico-pathologic and immunohistochemical characteristics were correlated in a multivariate Cox regression analysis with overall survival (OS), cancer-related survival (CRS) and disease-free survival (DFS).
  
  
  RESULTS
  Mean age of the patients was 62.7 years. The median follow-up was 67 months (9-124 months). HER-2/neu expression was detected in 18.2 % (n = 14), and PTEN expression in 72.7 % (n = 56) of our patients. Multivariate Cox regression analysis showed that patient's age, FIGO staging and HER-2/neu expression were independent prognostic factors for OS, CRS and DFS. PTEN expression did not significantly affect survival outcomes of the present study.
  
  
  CONCLUSIONS
  HER-2/neu but not PTEN expression is an independent prognostic factor for type I endometrial carcinoma.
authors.affiliation: 4th Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Konstantinoupoleos 49, 56224, Thessaloníki, Greece.
authors.forename: Ioannis
authors.initials: I
authors.lastname: Kalogiannidis
authors.forename: Stamatios
authors.initials: S
authors.lastname: Petousis
authors.forename: Mattheos
authors.initials: M
authors.lastname: Bobos
authors.forename: Chrysoula
authors.initials: C
authors.lastname: Margioula-Siarkou
authors.forename: Maria
authors.initials: M
authors.lastname: Topalidou
authors.forename: Alexis
authors.initials: A
authors.lastname: Papanikolaou
authors.forename: Ignace
authors.initials: I
authors.lastname: Vergote
authors.forename: Theodoros
authors.initials: T
authors.lastname: Agorastos
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology; D018269:Carcinoma, Endometrioid / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000401:mortality / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D006115:Greece; D006801:Humans; D015999:Multivariate Analysis; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D051059:PTEN Phosphohydrolase / Q000378:metabolism*; D011379:Prognosis; D016016:Proportional Hazards Models; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D015996:Survival Rate; D046888:Tissue Array Analysis; D016896:Treatment Outcome
chemical_list: D051059:PTEN Phosphohydrolase; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human; C494929:PTEN protein, human